Drug Discovery Technology Alert. Novel Drug to Treat Bile Acid Synthesis Disorders; Drug for Treatment of Thyroid Cancer Receives FDA Approval; Drug Screening Technology Platform Based on Modulation of Integrin Activity

USD 950

* Required Fields

USD 950

PAY BY INVOICE

Be the first to review this product

This issue profiles a novel drug to treat bile acid synthesis disorders, FDA approval for a drug for treatment of thyroid cancer, and a drug screening technology platform based on modulation of integrin activity.

Table of Contents

Drug Discovery Technology Alert. Novel Drug to Treat Bile Acid Synthesis Disorders; Drug for Treatment of Thyroid Cancer Receives FDA Approval; Drug Screening Technology Platform Based on Modulation of Integrin ActivityIn This Issue1. NOVEL DRUG TO TREAT BILE ACID SYNTHESIS DISORDERS2. DRUG FOR TREATMENT OF THYROID CANCER RECEIVES FDA APPROVAL3. FAST-ACTING, LONG-LASTING ANTI-MALARIAL DRUG CANDIDATE4. DRUG RECEIVES FAST TRACK APPROVAL FOR RARE PEDIATRIC CANCER5. NOVEL ANTI-HYPERTENSIVE DRUG RECEIVES FDA APPROVAL6. DRUG SCREENING TECHNOLOGY PLATFORM BASED ON MODULATION OF INTEGRIN ACTIVITY7. BREAKTHROUGH IN THE TREATMENT OF BRAIN CANCER8. GLOBAL PATENTS FOR TREATMENT OF PSORIASIS




Related Research

Release Date : 19-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.